Targeting CDK2-Cyclin E for Treating Solid Cancers
- Unveiling how CDK2/CyclinE dual degraders are more effective than CDK2 inhibitors
- Exploring how CDK2/CyclinE dual degraders overcome resistance to CDK4/6 inhibitors
- Explaining how functional Rb is not required for efficacy